54767414SMM3001 – A Phase 3 Randomized, Multicenter Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects with High-risk Smoldering Multiple Myeloma.
1. WHAT TYPE OF CANCER? WHAT STAGE?
Smoldering Multiple Myeloma.
2. WHO IS ELIGIBLE?
Diagnosed within 5 years.
3. HOW WILL I BE TREATED?
Daratumumab (an anti-body-based drug, directed against CD38).
For Physicians: More information about this specific trial at clinicaltrials.gov